Novartis profit rose last quarter, boosted by new cancer drugs https://t.co/XDZFh4UkmE ...

Core Insights - Johnson & Johnson (NYSE: JNJ) is expected to report the strongest numbers among pharmaceutical companies, according to Jim Cramer [1] - The stock has shown resilience despite ongoing talc lawsuits, with a recent increase in value indicating a potential shift in market sentiment [1] - CEO Joaquin Duato highlighted advancements in cancer drugs and medical devices, particularly in cardiology, suggesting a positive outlook for the company's product pipeline [2] Company Overview - Johnson & Johnson develops, manufactures, and markets healthcare products across pharmaceuticals and medical technologies [2] - The company is actively engaged in fighting talc-related lawsuits, with a belief that the risk from asbestos litigation has peaked as J&J has been winning cases [2] Market Position - Despite the potential of JNJ, there are opinions that certain AI stocks may offer greater upside potential with less downside risk [2]

Core Viewpoint - Allogene Therapeutics announced that its licensor, Cellectis, is facing a lawsuit in the U.S. regarding patent infringement related to gene editing technology [2] Company Summary - Allogene Therapeutics is involved in the development of cancer drugs and is impacted by the legal issues surrounding its licensor, Cellectis [2] - The lawsuit could have implications for Allogene's operations and its relationship with Cellectis, which is crucial for its gene editing technology [2] Industry Summary - The gene editing technology sector is facing legal challenges that may affect companies involved in this field, highlighting the importance of intellectual property rights [2]

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, and commented: “What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby po ...

while Lily is revealing the first of four new US manufacturing sites and it will be in Virginia. So this $5 billion site will specialize in making active pharmaceutical ingredients and drug product for Lily's cancer and autoimmune disease medicines as well as other advanced therapies. So the new factory will give Lily the ability to make targeted chemotherapies or antibody drug conjugates for the first time and the goal here is twofold.Creating new manufacturing capacity and bringing more of that manufactur ...

Group 1 - Truist Securities initiated coverage of Janux Therapeutics with a Buy recommendation [2] - A target price of $100 was set for Janux Therapeutics [2] - The recommendation is based on a catalyst-rich period expected for the company in the second half of the year [2]